Anti-P. aeruginosa PcrV Recombinant Antibody (MAb 166) (MRO-156MZ) (CAT#: MRO-156MZ)

This monoclonal antibody specific for Pseudomonas aeruginosa–encoded PcrV can be potentiall used in the treatment of an acute lung infection caused by Pseudomonas aeruginosa.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
ELISA

Figure 1 Competition ELISA between MAb 166 and Fab 1A8.

Figure 1 Competition ELISA between MAb 166 and Fab 1A8.

Fab 1A8 (50 nM) was mixed with various concentrations of either MAb 166 or MAb 3.7.5, and residual binding of Fab 1A8 to GST-PcrV was detected using anti-human kappa-HRP conjugate.

An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity

Inhib

Figure 2 Inhibition of Pseudomonas exotoxin-dependent cytotoxicity by Fab 1A8.

Figure 2 Inhibition of Pseudomonas exotoxin-dependent cytotoxicity by Fab 1A8.

X63 cells were incubated with PA103 (MOI = 10) for 3 h in the presence of various concentrations of Fab 1A8, MAb 166, or control Fab with no binding to PcrV or other P. aeruginosa proteins. Percent cytotoxicity was determined by PI staining and flow cytometry. Data are from three independent assays. Mean IC50 values ± SE are shown. A t test analysis showed no significant difference between MAb 166 IgG and Fab 1A.

An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity

FuncS

Figure 3 Time course of survival of mice treated with various doses of antibodies to PcrV at the time of challenge with a lethal dose of PA103.

Figure 3 Time course of survival of mice treated with various doses of antibodies to PcrV at the time of challenge with a lethal dose of PA103.

MAb 166 and Fab fragments were coinstilled with 1.5 × 106 bacteria via the intratracheal route (five mice per group, with four mice for MAb 166 Fab groups). The control was a nonspecific Fab with no binding to PcrV or any P. aeruginosa protein. Mice were treated with antibody doses of 10 μg (A), 5 μg (B), 2.5 μg (C) 1.25 μg (*, P = 0.01 for Fab 1A8 versus MAb 166 Fab) (D), 0.625 μg (*, P = 0.002 for 1A8 versus MAb 166 Fab) (E), 0.3125 μg (F), 0.16 μg (G), and 0.08 μg (H). P values for differences between treatment groups were determined by a Mantel-Cox log-rank test.

An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity

FuncS

Figure 4 Body temperature analysis of mice treated with anti-PcrV antibodies.

Figure 4 Body temperature analysis of mice treated with anti-PcrV antibodies.

Rectal temperatures are shown for 48 h or until mortality (means ± SE). Antibody doses were 10 μg. *, P < 0.05 for differences in body temperature between control mice and mice treated with MAb 166 IgG, MAb 166 Fab, or human Fab 1A8 at 10-μg or 5-μg doses (unpaired t test).

An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity

WB

Figure 5 Monoclonal antibody (MAb) 166 binds to the carboxyl-terminus of PcrV.

Figure 5 Monoclonal antibody (MAb) 166 binds to the carboxyl-terminus of PcrV.

Full-length (aa 1–294), different parts (aa 1–46, 1–76, 1–134, 1–172, and 139–294), and internal deletions (aa 1–75 and 173–294) of pcrV were subcloned for expression as glutathione S–transferase (GST)–tagged fusion proteins in the vector pGEX-2TK. The restriction site used for the initial construct is indicated, and the size of the expressed protein (in kDa) is indicated in parentheses. Bacterial lysates were prepared after induction and were analyzed for antibody binding by Western blot analysis. An immunoblot gel from an assay using rabbit (Rab) anti-PcrV as the primary antibody is shown (top). The data indicate that the clones are expressed and in frame with the predicted protein. Also shown is a gel from the same assay, except that MAb 166 was used as the primary antibody (bottom). MAb 166 bound to full-length clones and a carboxyl-terminal expression clone but not to amino-terminal clones or an internal deletion protein.

Generation and Characterization of a Protective Monoclonal Antibody to Pseudomonas aeruginosa PcrV


Specifications

  • Host Species
  • Mouse
  • Specificity
  • Pseudomonas aeruginosa
  • Clone
  • MAb 166
  • Applications
  • WB, ELISA, Inhib, FuncS
  • Related Disease
  • An acute lung infection caused by P. aeruginosa

Applications

  • Application Notes
  • The P. aeruginosa PcrV antibody has been reported in applications of Western Blot, Enzyme-linked Immunosorbent Assay, Inhibition, Functional Assay.

Target

  • Alternative Names
  • P. aeruginosa PcrV

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone MAb 166"

See other products for "P. aeruginosa PcrV"

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for MRO-156MZ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare